Comparison of antibody immune responses between BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in naïve and previously infected individuals

Abstract Background Two mRNA vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273, obtained the Emergency Use Listing by WHO for preventing COVID-19. However, little is known about the difference in antibody responses induced by these two mRNA vaccines in naïve and previously infected (PI) individuals. M...

Full description

Saved in:
Bibliographic Details
Published in:Journal of travel medicine 2021-12, Vol.28 (8)
Main Authors: Al-Sadeq, Duaa W, Shurrab, Farah M, Ismail, Ahmed, Amanullah, Fathima Humaira, Thomas, Swapna, Aldewik, Nader, Yassine, Hadi M, Abdul Rahim, Hanan F, Abu-Raddad, Laith, Nasrallah, Gheyath K
Format: Article
Language:English
Subjects:
2019-nCoV Vaccine mRNA-1273
Antibodies
Antibodies, Viral
Antibody Formation
BNT162 Vaccine
COVID-19
COVID-19 Vaccines
Humans
Immune response
Immunity
Immunoglobulin A
Immunoglobulin G
mRNA
mRNA Vaccines
Original
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Two mRNA vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273, obtained the Emergency Use Listing by WHO for preventing COVID-19. However, little is known about the difference in antibody responses induced by these two mRNA vaccines in naïve and previously infected (PI) individuals. Method We investigated the levels of anti-S-RBD (total, IgG and IgA) levels in naïve and PI individuals, 1–13 (median = 6) weeks following the second dose of either vaccine. Results in the naïve-vaccinated group, the mRNA-1273 vaccine induced significantly higher levels of anti-S-RBD total antibodies (3.5-fold; P 
ISSN:1195-1982
1708-8305
DOI:10.1093/jtm/taab190